Small Interfering Ribonucleic Acid (RNA) Market Outlook 2026–2030 Driven By Growth Factors And Projections
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Small Interfering Ribonucleic Acid (RNA) Market Projected To Reach By 2030?
The small interfering ribonucleic acid (rna) market size has undergone significant expansion in recent years. It is anticipated to increase from $18.86 billion in 2025 to $22.69 billion in 2026, achieving a compound annual growth rate (CAGR) of 20.3%. The market’s past growth can be linked to advancements in molecular biology research, a growing occurrence of genetic and chronic illnesses, the initial successes of rna-based therapies, enhanced research funding in genomics, and the establishment of rna interference mechanisms.
The small interfering ribonucleic acid (rna) market size is projected to experience rapid expansion in the coming years. This market is predicted to reach $47.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.0%. Factors driving this growth during the projected period include a rise in regulatory clearances for rna-based treatments, a greater need for individualized medicine, advancements in nanoparticle delivery technologies, increased funding from pharmaceutical firms, and the expanded use of sirna for infectious and rare conditions. Key trends anticipated in this forecast timeframe encompass a wider clinical integration of rna interference treatments, an intensified focus on precise gene silencing methods, the proliferation of sophisticated sirna delivery systems, an uptick in investments for developing precision therapeutics, and a stronger emphasis on scalable rna production.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30394&type=smp
What Primary Drivers Are Shaping The Small Interfering Ribonucleic Acid (RNA) Market?
The escalating need for personalized medicine is projected to stimulate the expansion of the small interfering ribonucleic acid (RNA) market in the future. Personalized medicine represents a healthcare strategy focused on customizing treatments for individual patients based on their genetic, environmental, and lifestyle attributes to optimize results and elevate care. The heightened demand for personalized medicine is driven by breakthroughs in genomic technologies, which allow for the accurate identification of genetic variations and the development of tailored therapies for individuals. Small interfering ribonucleic acid (siRNA) improves personalized medicine through targeted gene silencing, making it highly effective for managing specific genetic disorders and conditions. It diminishes unintended effects by precisely inhibiting disease-causing mRNA, thereby enhancing therapeutic effectiveness and patient outcomes. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, stated that the U.S. Food and Drug Administration (FDA) authorized 26 new personalized medicines in 2023, which is a considerable rise from the 12 approved in 2022. Thus, the increasing demand for personalized medicine is a significant catalyst for the growth of the small interfering ribonucleic acid (RNA) market.
How Is The Small Interfering Ribonucleic Acid (RNA) Market Categorized Across Its Segment Groups?
The small interfering ribonucleic acid (rna) market covered in this report is segmented –
1) By Type: Liposome Systemic Therapy, Nanoparticle-Based Systemic Therapy
2) By Indication: Cardiovascular Diseases, Respiratory Diseases, Oncology, Neurodegenerative Diseases, Infectious Diseases
3) By End-User: Hospital, Research Institutions, Pharmaceutical And Biotechnology Companies, Academic Institutions
Subsegments:
1) By Liposome Systemic Therapy: Cationic Liposome Delivery, Neutral Liposome Delivery, Pegylated Liposome Delivery, Targeted Liposome Delivery
2) By Nanoparticle-Based Systemic Therapy: Lipid Nanoparticle Delivery, Polymer Nanoparticle Delivery, Gold Nanoparticle Delivery, Silica Nanoparticle Delivery
What Trends Are Affecting The Direction Of The Small Interfering Ribonucleic Acid (RNA) Market?
Leading companies in the small interfering ribonucleic acid (siRNA) therapeutics market are concentrating on securing regulatory approvals for innovative mechanisms aimed at treating rare genetic diseases, intending to offer sustained effects and reduce the frequency of dosing for patients. Regulatory approvals signify official clearances granted by authorities, permitting a drug or therapy to be safely tested, marketed, or used for patients. For instance, in March 2025, Alnylam Pharmaceuticals Inc., a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for Qfitlia (fitusiran). This marked the first small interfering ribonucleic acid (siRNA)-based therapy for adults and adolescents aged 12 years and older diagnosed with hemophilia A or B, regardless of inhibitor presence. It functions by lowering antithrombin levels, thereby enhancing thrombin generation to foster clot formation and diminish bleeding episodes. Qfitlia offers a subcutaneous, once-every-two-month dosing regimen, presenting a novel, non-factor therapeutic choice for hemophilia management.
Which Firms Are Influencing Competition In The Small Interfering Ribonucleic Acid (RNA) Market?
Major companies operating in the small interfering ribonucleic acid (rna) market are Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Sanofi S.A., Sarepta Therapeutics Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.
Get The Full Small Interfering Ribonucleic Acid (RNA) Market Report:
Which Region Is The Top Contributor To The Small Interfering Ribonucleic Acid (RNA) Market By Share?
North America was the largest region in the small interfering ribonucleic acid (RNA) market in 2025. The regions covered in the small interfering ribonucleic acid (rna) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Small Interfering Ribonucleic Acid (RNA) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Small Interfering Ribonucleic Acid (RNA) Market 2026, By The Business Research Company
Ribonucleic Acid Rna Sequencing Market Report 2026
Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026
Nucleic Acid Isolation And Purification Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
